International medicines regulations : a forward look to 1992
著者
書誌事項
International medicines regulations : a forward look to 1992
(CMR workshop series)
Kluwer Academic Publishers, c1989
大学図書館所蔵 全1件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Proceedings of the Centre for Medicines Research Workshop held at the CIBA Foundation, London, 20th/21st September 1988
内容説明・目次
内容説明
As 1992 looms on the horizon and preparation is made for the completion of the internal market in Europe, the CMR realised the value of addressing some of the issues involved and defining the objectives and achievements of medicines regulations in a number of EEC countries in comparison with Japan and the USA. The overall aim was to use the lessons of past experience to determine the most appropriate way forward. The final debate focused on two possibilities for assessing and granting marketing authorisations for Europe, namely mutual recognition or a centrally organised European Med- icines Office. These two views were discussed in detail at both the workshop at the Ciba Foundation and the international symposium at the Royal College of Physicians. It is hoped that this sharing of ideas and the publication of the proceedings of this fifth CMR Workshop will have encouraged all concerned to continue the debate so that the final outcome will be the establishment of an efficient system in the community for the benefit of patients, the practising physician and the pharmaceutical industry. We would like to take this opportunity of thanking Brenda Mullinger for the considerable amount of scientific and editorial work that she carried out on the manuscripts, Sheila Wright for providing the secretarial support which allowed the proceedings to be submitted to Kluwer Academic Publishers on disk and Sandra Cox who organised the administrative aspects so vital to the successful running of a Workshop and major international symposium. S. R.
目次
Section I Historical Development and Role of Regulations.- 1 The historical development of medicines regulations.- 2 Setting the scene - the role of regulation.- 3 An international comparison of medicines regulations.- Discussions points.- Section II Objectives and Achievements of Regulations.- 4 Objectives and achievements of regulations in West Germany.- 5 Objectives and achievements of regulations in West Germany.- 6 Objectives and achievements of medicines regulations in the BENELUX countries.- 7 Objectives and achievements of regulations in The Netherlands.- 8 Objectives and achievements of regulations in the UK.- 9 Objectives and achievements of medicines regulations in the UK.- 10 The Swedish medicines regulatory system - with some notes on the Scandinavian situation.- 11 Objectives and achievements of medicines regulations in the Nordic countries.- 12 Objectives and achievements of regulations in the USA.- 13 Objectives and achievements of regulations in the USA.- 14 Objectives and achievements of regulations in Japan.- 15 Objectives and achievements of regulations in developing countries.- Discussion points.- 16 Overview of objectives and achievements of medicines regulations.- Section III Future Perspectives of Regulations in Japan and the United States.- 17 Future perspectives of regulations in Japan.- 18 Future perspectives of regulations in the United States.- 19 Future perspectives of regulations - industry viewpoint.- Discussion points.- Section IV Future Perspectives of Regulations in the European Economic Community.- 20 The role of the CPMP in the EEC.- 21 Future perspectives of regulations - internal market by 1992?.- 22 Future perspectives of regulations - harmonization of data requirements.- 23 Future perspectives of regulations - national authorities' relationship with the EEC.- 24 Future perspectives of regulations - the concept of a European medicines office.- 25 Mutual recognition or a central European office?.- Discussion points.- Final round table discussion.- Appendix 1 The future systems in Europe.- ABPI Steering Group for Europe.- Appendix 2 Memorandum on the future system for the authorization of medicinal products in the European.- Community.- Commission of the European Communities Memorandum.
「Nielsen BookData」 より